Company news
Sanofi Sa (EURONEXT:SAN) news
Sanofi Sa news releases on 6ix. Latest, Dec 23, 2025: Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma
Press releases — page 3
Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma
December 23, 2025
Sanofi: Information concerning the total number of voting rights and shares - November 2025
December 22, 2025
Press Release: Sanofi reaches agreement with the US government to lower medicine costs while strengthening innovation
December 19, 2025
Press release: Availability of the Q4 2025 Aide memoire
December 17, 2025
Press Release: Sanofi’s efdoralprin alfa earns orphan designation in the EU for alpha-1 antitrypsin deficiency related emphysema
December 17, 2025
Market update
December 16, 2025
Press Release: Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis
December 15, 2025
Press Release: Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseases
December 11, 2025
InduPro Therapeutics Announces Strategic Investment from Sanofi and a Research Collaboration to Advance a Novel Bispecific for Autoimmune Disorders
December 10, 2025
Blueprint Medicines, a Sanofi Company, Highlights Long-Term Clinical Benefit of AYVAKIT® (avapritinib) Across Indolent and Advanced Systemic Mastocytosis at 2025 ASH Annual Meeting
December 5, 2025
Press Release: Sanofi completes acquisition of Vicebio
December 4, 2025
Press Release: Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria
November 25, 2025
Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)
November 25, 2025
DarioHealth Announces Publication of Sanofi Study in JMIR Demonstrating an Estimated $5,077 Medical Cost Savings Per Dario Digital Health Platform User Per Year
November 24, 2025
SANOFI WINS THE 2025 PRIX GALIEN CANADA INNOVATIVE PRODUCT AWARD
November 20, 2025
Lifordi Immunotherapeutics Secures Strategic Investment from Sanofi Ventures and Additional Capital from Existing Investors
November 18, 2025
Press Release: Sanofi’s Teizeild recommended for EU approval by the CHMP for patients with stage 2 type 1 diabetes
November 14, 2025
Sanofi: Information concerning the total number of voting rights and shares – October 2025
November 13, 2025
Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates
November 12, 2025
MacroGenics Reports Third Quarter 2025 Financial Results and Provides Update on Corporate Progress
November 12, 2025
Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review
November 7, 2025
Dupixent® (dupilumab) Pivotal Trial Met All Primary and Secondary Endpoints, Reducing Signs and Symptoms of Allergic Fungal Rhinosinusitis (AFRS); sBLA Accepted for FDA Priority Review
November 7, 2025
Rezurock® now covered in Quebec for people living with chronic graft-versus-host disease (GVHD)
November 6, 2025
Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovid™, Triggering a $25 Million Milestone Payment
November 4, 2025
United States Multiple Myeloma Market Research Report 2025-2033, Profiles of Key Players - Novartis, Abbvie, Sanofi, Johnson and Johnson, Baxter, Pfizer, Takeda, and Bristol-Myers Squibb
November 3, 2025
Update: Dassault Systèmes: Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey
October 28, 2025
Press release: Sanofi successfully prices USD 3 billion of bond issue
October 28, 2025
UPDATE - Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey
October 26, 2025
Press release: Q3: continued sales and earnings progress
October 24, 2025
Sanofi Deepens Partnership with Medidata to Expedite the Development of New Therapies with an Improved Patient Journey
October 23, 2025
Electra Therapeutics Announces $183 Million Series C Financing to Advance First-in-Class SIRP-Targeted Therapies for Immune Disorders and Cancer
October 22, 2025
Press Release: Sanofi’s efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study
October 22, 2025
/C O R R E C T I O N -- Sanofi-Aventis Canada Inc./
October 21, 2025
Press Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors
October 20, 2025
Press Release: Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose
October 20, 2025
Press Release: Sanofi’s Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopenia
October 17, 2025
Press Release: Sanofi provides update on regulatory review in the EU for Rezurock to treat chronic graft-vs-host disease
October 17, 2025
EVOQ Therapeutics Announces Collaboration and License Agreement with Sanofi
October 16, 2025
Sanofi: Information concerning the total number of voting rights and shares - September 2025
October 14, 2025
BenchSci Announces Three-Year License Agreement with Sanofi to Access and Use BenchSci’s ASCEND Platform
October 8, 2025
Press Release: AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors
October 8, 2025
Novavax Continues to Deliver on Sanofi Partnership, Completing Nuvaxovid® EU Marketing Authorization Transfer and Triggering $25 Million Milestone Payment
October 7, 2025
Sanofi: Investițiile în prevenție susțin sănătatea și competitivitatea Europei
May 7, 2025
Sanofi: A megelőzésbe való befektetés Európa egészségének és versenyképességének alapja
May 7, 2025
Sanofi: Investing in prevention builds Europe’s health and competitiveness
May 6, 2025